Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1993 Jun;52(6):429–435. doi: 10.1136/ard.52.6.429

Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products.

K L Lim 1, A C Jones 1, N S Brown 1, R J Powell 1
PMCID: PMC1005067  PMID: 8323394

Abstract

OBJECTIVES--To investigate urine neopterin as a parameter of disease activity in an unselected group of patients with systemic lupus erythematosus (SLE) and to study the relation between urine neopterin and certain patterns of organ disease and differing drug regimens in the treatment of SLE. METHODS--Neopterin was determined by high performance liquid chromatography in 115 early morning urine samples from 68 patients with SLE. Serum soluble interleukin 2 receptor (sIL-2R) and antibodies to double stranded DNA (dsDNA) were determined by enzyme linked immunosorbent assay (ELISA), and the erythrocyte sedimentation rate (ESR), plasma C3, C4, and C3 degradation products (C3dg) were measured in corresponding blood samples. Disease activity was scored using the British Isles Lupus Assessment Group (BILAG) index. RESULTS--Urine neopterin was significantly increased in patients with active and inactive SLE compared with the control group and was significantly higher in patients with active than in those with inactive SLE. Urine neopterin did not distinguish between subsets of patients with SLE with particular patterns of organ disease, as defined by the BILAG index, nor was its level primarily influenced by differing drug regimens. Levels of serum sIL-2R, antibodies to dsDNA, the ESR, and plasma C3, C4, and C3dg were also significantly different between the patients with active and inactive SLE. Unlike urine neopterin there was considerable overlap in the values of these parameters between the two activity groups. Highly significant correlations found between urine neopterin and serum sIL-2R, ESR, and plasma C3, C4, and C3dg suggest the close association of neopterin with clinical activity in SLE. Multivariate logistic regression analysis showed that urine neopterin > 300 mumol/mol creatinine was a highly significant predictor of disease activity with an odds ratio of 3.51. CONCLUSIONS--Determination of urine neopterin, a non-invasive, relatively simple and inexpensive measurement, appears to be the best parameter for assessing and monitoring disease activity and treatment in patients with SLE.

Full text

PDF
429

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Airo P., Braga S., Prati E., Brugnoni D., Bettinzioli M., Gorla R., Cattaneo R. Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus. Clin Rheumatol. 1992 Mar;11(1):97–100. doi: 10.1007/BF02207093. [DOI] [PubMed] [Google Scholar]
  2. Andert S. E., Griesmacher A., Zuckermann A., Müller M. M. Neopterin release from human endothelial cells is triggered by interferon-gamma. Clin Exp Immunol. 1992 Jun;88(3):555–558. doi: 10.1111/j.1365-2249.1992.tb06486.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Campen D. H., Horwitz D. A., Quismorio F. P., Jr, Ehresmann G. R., Martin W. J. Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation. Arthritis Rheum. 1988 Nov;31(11):1358–1364. doi: 10.1002/art.1780311103. [DOI] [PubMed] [Google Scholar]
  4. Hishikawa T., Tokano Y., Sekigawa I., Ando S., Takasaki Y., Hashimoto H., Hirose S., Okumura K., Abe M., Shirai T. HLA-DP+ T cells and deficient interleukin-2 production in patients with systemic lupus erythematosus. Clin Immunol Immunopathol. 1990 May;55(2):285–296. doi: 10.1016/0090-1229(90)90104-x. [DOI] [PubMed] [Google Scholar]
  5. Huang Y. P., Perrin L. H., Miescher P. A., Zubler R. H. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol. 1988 Aug 1;141(3):827–833. [PubMed] [Google Scholar]
  6. Huber C., Batchelor J. R., Fuchs D., Hausen A., Lang A., Niederwieser D., Reibnegger G., Swetly P., Troppmair J., Wachter H. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med. 1984 Jul 1;160(1):310–316. doi: 10.1084/jem.160.1.310. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Huber C., Fuchs D., Hausen A., Margreiter R., Reibnegger G., Spielberger M., Wachter H. Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol. 1983 Mar;130(3):1047–1050. [PubMed] [Google Scholar]
  8. Leohirun L., Thuvasethakul P., Sumethkul V., Pholcharoen T., Boonpucknavig V. Urinary neopterin in patients with systemic lupus erythematosus. Clin Chem. 1991 Jan;37(1):47–50. [PubMed] [Google Scholar]
  9. Manoussakis M. N., Germanidis G. S., Drosos A. A., Moutsopoulos H. M. Impaired urinary excretion of soluble IL-2 receptors in patients with systemic lupus erythematosus and rheumatoid arthritis. Lupus. 1992 Feb;1(2):105–109. doi: 10.1177/096120339200100208. [DOI] [PubMed] [Google Scholar]
  10. Manoussakis M. N., Papadopoulos G. K., Drosos A. A., Moutsopoulos H. M. Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune diseases. Clin Immunol Immunopathol. 1989 Mar;50(3):321–332. doi: 10.1016/0090-1229(89)90140-2. [DOI] [PubMed] [Google Scholar]
  11. Niederwieser A., Joller P., Seger R., Blau N., Prader A., Bettex J. D., Lüthy R., Hirschel B., Schaedelin J., Vetter U. Neopterin in AIDs, other immunodeficiencies, and bacterial and viral infections. Klin Wochenschr. 1986 Apr 1;64(7):333–337. doi: 10.1007/BF01711954. [DOI] [PubMed] [Google Scholar]
  12. Niederwieser D., Fuchs D., Hausen A., Judmaier G., Reibnegger G., Wachter H., Huber C. Neopterin as a new biochemical marker in the clinical assessment of ulcerative colitis. Immunobiology. 1985 Nov;170(4):320–326. doi: 10.1016/S0171-2985(85)80080-2. [DOI] [PubMed] [Google Scholar]
  13. Prior C., Bollbach R., Fuchs D., Hausen A., Judmaier G., Niederwieser D., Reibnegger G., Rotthauwe H. W., Werner E. R., Wachter H. Urinary neopterin, a marker of clinical activity in patients with Crohn's disease. Clin Chim Acta. 1986 Feb 28;155(1):11–21. doi: 10.1016/0009-8981(86)90094-x. [DOI] [PubMed] [Google Scholar]
  14. Rabinoff M. Possible uses of urinary neopterin and biopterin measurement. Med Hypotheses. 1989 Aug;29(4):241–243. doi: 10.1016/0306-9877(89)90105-9. [DOI] [PubMed] [Google Scholar]
  15. Raziuddin S., Nur M. A., al-Wabel A. A. Increased circulating HLA-DR+ CD4+ T cells in systemic lupus erythematosus: alterations associated with prednisolone therapy. Scand J Immunol. 1990 Feb;31(2):139–145. doi: 10.1111/j.1365-3083.1990.tb02753.x. [DOI] [PubMed] [Google Scholar]
  16. Rubin L. A. The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum. 1990 Aug;33(8):1145–1148. doi: 10.1002/art.1780330814. [DOI] [PubMed] [Google Scholar]
  17. Semenzato G., Bambara L. M., Biasi D., Frigo A., Vinante F., Zuppini B., Trentin L., Feruglio C., Chilosi M., Pizzolo G. Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol. 1988 Nov;8(6):447–452. doi: 10.1007/BF00916949. [DOI] [PubMed] [Google Scholar]
  18. Slazyk W. E., Spierto F. W. Liquid-chromatographic measurement of biopterin and neopterin in serum and urine. Clin Chem. 1990 Jul;36(7):1364–1368. [PubMed] [Google Scholar]
  19. Symmons D. P., Coppock J. S., Bacon P. A., Bresnihan B., Isenberg D. A., Maddison P., McHugh N., Snaith M. L., Zoma A. S. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988 Nov;69(259):927–937. [PubMed] [Google Scholar]
  20. Tabata H., Hara M., Kitani A., Hirose T., Norioka K., Harigai M., Suzuki K., Kawakami M., Kawagoe M., Nakamura H. Expression of TLiSA1 on T cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol. 1989 Sep;52(3):366–375. doi: 10.1016/0090-1229(89)90151-7. [DOI] [PubMed] [Google Scholar]
  21. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  22. Via C. S., Handwerger B. S. T-cell and B-cell function in lupus. Curr Opin Rheumatol. 1992 Oct;4(5):630–634. [PubMed] [Google Scholar]
  23. Wachter H., Fuchs D., Hausen A., Reibnegger G., Werner E. R. Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem. 1989;27:81–141. doi: 10.1016/s0065-2423(08)60182-1. [DOI] [PubMed] [Google Scholar]
  24. Ward M. M., Dooley M. A., Christenson V. D., Pisetsky D. S. The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus. J Rheumatol. 1991 Feb;18(2):235–240. [PubMed] [Google Scholar]
  25. Werner E. R., Bichler A., Daxenbichler G., Fuchs D., Fuith L. C., Hausen A., Hetzel H., Reibnegger G., Wachter H. Determination of neopterin in serum and urine. Clin Chem. 1987 Jan;33(1):62–66. [PubMed] [Google Scholar]
  26. Wigfall D. R., Sakai R. S., Wallace D. J., Jordan S. C. Interleukin-2 receptor expression in peripheral blood lymphocytes from systemic lupus erythematosus patients: relationship to clinical activity. Clin Immunol Immunopathol. 1988 Jun;47(3):354–362. doi: 10.1016/s0090-1229(88)80012-6. [DOI] [PubMed] [Google Scholar]
  27. Wolf R. E., Brelsford W. G. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988 Jun;31(6):729–735. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  28. ter Borg E. J., Horst G., Hummel E. J., Limburg P. C., Kallenberg C. G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990 May;33(5):634–643. doi: 10.1002/art.1780330505. [DOI] [PubMed] [Google Scholar]
  29. ter Borg E. J., Horst G., Hummel E., Limburg P. C., Kallenberg C. G. Rises in anti-double stranded DNA antibody levels prior to exacerbations of systemic lupus erythematosus are not merely due to polyclonal B cell activation. Clin Immunol Immunopathol. 1991 Apr;59(1):117–128. doi: 10.1016/0090-1229(91)90086-p. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES